Thông tin thuốc gốc
Chỉ định và Liều dùng
Prophylaxis of nausea and vomiting associated with cytotoxic therapy
Adult: 5 mg by slow IV inj over at least 1 min or by IV infusion over 15 min to be given 15 min before chemotherapy on day 1, followed by oral preparation on day 2-6.
Child: >2 yr 0.2 mg/kg (max: 5 mg) by slow IV inj over at least 1 min or by IV infusion at a concentration of 0.05 mg/ mL over 15 min to be given as a single dose before chemotherapy on day 1. >25 kg: Continue once daily at the same dose up to day 5 of chemotherapy.

Treatment and prophylaxis of postoperative nausea and vomiting
Adult: 2 mg as single dose or once daily by bolus inj over 30 sec or by IV infusion over 15 min w/in 2 hr at the end of anaesth (treatment) or before induction of anaesth (prophylaxis).

Prophylaxis of nausea and vomiting associated with cytotoxic therapy
Adult: 5 mg once daily before chemotherapy on day 2-6 following IV dose given on day 1. Duration of treatment: 5 days.
Child: >2 yr 0.2 mg/kg once daily before chemotherapy on day 2-6 following IV dose given on day 1. Duration of treatment: 5 days.
Special Patient Group
Patient w/ uncontrolled HTN: Max dose: 10 mg daily.
Cách dùng
Should be taken on an empty stomach. Take in the morning immediately upon rising 1 hr before breakfast.
Hướng dẫn pha thuốc
IV infusion: Dilute in 100 mL of NaCl 0.9%, glucose 5% inj, Ringer’s soln, mannitol 10%, or KCl 0.3% soln.
Chống chỉ định
Pregnancy and lactation.
Thận trọng
Patient w/ cardiac rhythm or conduction disturbances, uncontrolled HTN. Risk of QT interval prolongation, electrolyte disturbances. Childn.
Phản ứng phụ
Significant: QT prolongation. Rarely, hypersensitivity reactions (e.g. anaphylaxis).
Nervous: Headache, constipation, dizziness, fatigue, visual hallucinations, somnolence, syncope.
CV: HTN, hypotension.
GI: Abdominal pain, diarrhoea, anorexia.
Resp: Dyspnoea, acute bronchospasm, chest discomfort.
Dermatologic: Urticaria.
Potentially Fatal: Rarely, collapse and CV arrest.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness or fatigue, if affected, do not drive or operate machinery.
Monitor BP, ECG and electrolyte abnormalities.
Quá liều
Symptoms: Visual hallucinations, increased BP. Management: Symptomatic treatment. Monitor vital signs closely.
Tương tác
Decreased plasma concentration w/ rifampicin or other liver enzyme-inducers (e.g. phenobarbital). Increased risk of conduction abnormalities w/ antiarrhythmics, β-blockers. Risk of serotonin syndrome w/ serotonergic drugs (e.g. serotonin and norepinephrine reuptake inhibitors [SNRIs or SSRIs]).
Tác dụng
Description: Tropisetron is a potent and selective serotonin (5-HT3) receptor antagonist. It competitively blocks serotonin peripherally on vagal nerve terminal and centrally in the chemoreceptor trigger zone.
Duration: 24 hr.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: W/in 3 hr. Bioavailability: 60%.
Distribution: Volume of distribution: 400-600 L. Plasma protein binding: 71%.
Metabolism: Undergoes hepatic first-pass metabolism by CYP2D6 via hydroxylation of its indole ring and via conjugation to glucuronide/sulfate.
Excretion: Mainly via urine (approx 8%, as unchanged drug; 70%, as metabolites); faeces (15%, as metabolites). Elimination half-life: Approx 8 hr (extensive metabolisers); 45 hr (poor metabolisers).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Tropisetron, CID=656665, (accessed on Jan. 23, 2020)

Bảo quản
Store below 25°C.
Phân loại MIMS
Phân loại ATC
A04AA03 - tropisetron ; Belongs to the class of serotonin (5HT3) antagonists. Used for the prevention of nausea and vomiting.
AFT Pharmaceuticals Ltd. Tropisetron AFT data sheet May 2017. Medsafe. Accessed 23/11/2017.

Anon. Tropisetron. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 23/11/2017.

Buckingham R (ed). Tropisetron. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 23/11/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tropisetron từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Navoban
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in